Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCNNASDAQ:ERNANASDAQ:GLYCNASDAQ:GRAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.11+0.6%$3.05$1.27▼$9.47$9.90M1.581.27 million shs12,129 shsERNAErnexa Therapeutics$2.53+5.9%$3.02$2.08▼$39.38$9.53M5.55191,487 shs97,979 shsGLYCGlycoMimetics$0.16-6.6%$21.78$14.06▼$63.00$10.00M1.6268,575 shs1.05 million shsGRAYGraybug Vision$1.70-1.2%$1.73$5.00▼$22.12$2.67M1.22,165 shs17,503 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+0.16%-0.96%+2.30%+22.44%+8.36%ERNAErnexa Therapeutics+5.86%+8.82%-24.70%-39.09%-91.44%GLYCGlycoMimetics0.00%-99.09%-99.37%-99.44%-99.35%GRAYGraybug Vision-1.16%-5.03%-15.00%-19.43%-64.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion Therapeutics1.5213 of 5 stars0.03.00.00.02.73.30.6ERNAErnexa Therapeutics0.9298 of 5 stars0.05.00.00.01.81.70.0GLYCGlycoMimetics1.7402 of 5 stars0.03.00.04.63.11.70.0GRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 0.00N/AN/AN/AERNAErnexa Therapeutics 0.00N/AN/AN/AGLYCGlycoMimetics 2.50Moderate BuyN/AN/AGRAYGraybug Vision 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRAY, ERNA, GLYC, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025GLYCGlycoMimeticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.08M4.80N/AN/A$3.27 per share0.95ERNAErnexa Therapeutics$580K18.15N/AN/A$0.50 per share5.06GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94GRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/5/2025 (Estimated)ERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)GRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/ALatest GRAY, ERNA, GLYC, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GLYCGlycoMimetics-$5.00-$4.00+$1.00-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A4.214.21ERNAErnexa TherapeuticsN/A0.210.21GLYCGlycoMimeticsN/A1.921.92GRAYGraybug VisionN/A10.7310.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%ERNAErnexa Therapeutics70.55%GLYCGlycoMimetics75.19%GRAYGraybug Vision49.94%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%ERNAErnexa Therapeutics4.49%GLYCGlycoMimetics8.70%GRAYGraybug Vision7.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataERNAErnexa Therapeutics104.16 million3.97 millionNo DataGLYCGlycoMimetics5064.53 million58.90 millionOptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionableGRAY, ERNA, GLYC, and CYCN HeadlinesRecent News About These CompaniesGraycliff Exploration and Emergent Waste Solutions Sign Letter of IntentMarch 3, 2025 | newsfilecorp.comGENAI ANNOUNCES CHANGE OF MANAGEMENT AND APPOINTMENT OF PATRICK GRAY AS CEOJanuary 6, 2025 | prnewswire.comOppenheimer Sticks to Its Buy Rating for CalciMedica (CALC)November 1, 2024 | markets.businessinsider.comAge-Related Macular DegenerationOctober 23, 2024 | benzinga.comChanging Faces – Pharma and biotech September 2024October 1, 2024 | pharmaphorum.comSeismic Therapeutic Appoints Julie Eastland as Independent Board DirectorSeptember 23, 2024 | finance.yahoo.comGlobal Age-Related Macular Degeneration Market to Reach US$ 19.72 Billion by 2032 from US$ 11.31 BillionSeptember 10, 2024 | taiwannews.com.twPhotobiomodulation for Early Dry AMD Gets Enthusiastic ReceptionJuly 25, 2024 | msn.comCould Metformin Fill the Bill for Geographic Atrophy Prevention?July 22, 2024 | msn.comGene Therapies for Neovascular AMD Continue to Show PromiseJuly 20, 2024 | msn.comDelveInsight Business Research, LLP: Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsightApril 26, 2024 | finanznachrichten.deCorneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsightApril 9, 2024 | prnewswire.co.ukOpthea looks to be key player in $US10 billion wet AMD marketMarch 6, 2024 | dailytelegraph.com.auDolby Vision HDR: everything you need to knowFebruary 11, 2024 | whathifi.comQuest Now Natively Supports Spatial Video Originally Meant for Vision ProFebruary 2, 2024 | roadtovr.comApple Vision Pro rumored release date, price, specs and latest newsJanuary 4, 2024 | tomsguide.comBest Vision Insurance Companies Of 2024January 4, 2024 | forbes.comApple's Next-Gen Vision Pro Headset Could Have One Major Display UpgradeDecember 30, 2023 | inverse.comBloomberg: Vision Pro production moving at full speed, February launch plannedDecember 22, 2023 | 9to5mac.comProgram: Rear VisionNovember 20, 2023 | abc.net.auNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International Markets3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneBy Thomas Hughes | June 4, 2025View 3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneGRAY, ERNA, GLYC, and CYCN Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.11 +0.02 (+0.65%) Closing price 06/17/2025 03:57 PM EasternExtended Trading$3.40 +0.29 (+9.32%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Ernexa Therapeutics NASDAQ:ERNA$2.53 +0.14 (+5.86%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$2.52 -0.01 (-0.24%) As of 06:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.GlycoMimetics NASDAQ:GLYC$0.16 -0.01 (-6.63%) Closing price 06/13/2025Extended Trading$0.16 0.00 (0.00%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Graybug Vision NASDAQ:GRAY$1.70 -0.02 (-1.16%) As of 06/16/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? Can Luckin and Dutch Bros Take Market Share From Starbucks? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
